Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumor in adults. Current treatment options typically consist of surgery followed by …

Glioblastoma is the most common and aggressive primary malignant brain tumour. The
prognosis of patients with glioblastoma is poor, and their overall survival averages at 1 year …

Immunotherapy failures can result from the highly suppressive tumour microenvironment
that characterizes aggressive forms of cancer such as recurrent glioblastoma (rGBM),. Here …

High-grade glioma is one of the deadliest primary tumors of the central nervous system.
Despite the many novel immunotherapies currently in development, it has been difficult to …

Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment
protocols and traditional immunotherapy are poorly effective as they do not significantly …

Glioblastoma, the most common and aggressive primary brain tumor type, is considered an
immunologically “cold” tumor with sparse infiltration by adaptive immune cells …

The limited benefits of immunotherapy against glioblastoma (GBM) is closely related to the
paucity of T cells in brain tumor bed. Both systemic and local immunosuppression contribute …

Myeloid cells are abundant, create a highly immunosuppressive environment in
glioblastoma (GBM), and thus contribute to poor immunotherapy responses. Based on the …

T cell dysfunction‐induced tumor immune escape is particularly severe in glioblastoma
(GBM), and significantly affects the efficacy of immunotherapy. It is crucial to innovatively …

Glioblastomas (GBM) are the most common and aggressive tumors of the central nervous
system. Rapid tumor growth and diffuse infiltration into healthy brain tissue, along with high …